丁螺环酮联合阿立哌唑治疗精神分裂症焦虑症状的临床疗效和安全性

目的 探讨丁螺环酮联合阿立哌唑治疗精神分裂症焦虑症状的临床疗效。方法 采用随机、抽样与对照研究方法，选择2014年2月-2017年1月在新乡医学院第二附属医院诊治的精神分裂症患者84例，伴有焦虑症状，根据信封随机分组法分为观察组与对照组各42例，对照组给予阿立哌唑治疗，观察组在对照组治疗的基础上给予丁螺环酮治疗，两组都治疗观察3个月。比较两组的临床疗效及HAMA评分、皮质醇水平变化，观察两组在治疗期间出现的嗜睡、便秘、口干、头晕等不良反应情况。结果 观察组的总有效率（95.2%）显著高于对照组（81.0%），差异有统计学意义（P<0.05）。治疗后观察组、对照组的HAMA评分分别为（4.86±1.49）分和（7.98±2.10）分，都显著低于治疗前的（22.98±4.52）分和（23.87±3.10）分，同组治疗前后比较差异有统计学意义（P<0.05）；观察组也显著低于对照组，差异有统计学意义（P<0.05）。治疗后两组的皮质醇水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；观察组治疗后皮质醇水平也显著低于对照组，差异有统计学意义（P<0.05）。治疗期间两组的嗜睡、便秘、口干、头晕等不良反应发生情况对比无显著差异。结论 丁螺环酮联合阿立哌唑治疗精神分裂症，能改善患者的焦虑症状和临床疗效，安全性也比较好。

The clinical efficacy and the effect on HAMD score of buspirone in the adjuvant treatment of schizophrenia agitation

Objective To investigate the clinical efficacy and the effect on HAMA score of buspirone in the adjuvant treatment of schizophrenia agitation. Methods Used a randomized, controlled study and sampling method, From February 2014 to January 2017, a total of 84 cases with schizophrenia agitation in our hospital were selected and were randomly divided into observation group and control group with 42 cases in each group accorded to the spirit of the envelope, the control group was given aripiprazole treatment, the observation group were given buspirone in the treatment based on the control group treatment, two groups were treated for 3 months. Results The total effective rates in the observation group and the control group were 95.2% and 81% respectively, and the observation group was significantly higher than that of the control group (P<0.05). After treatment, the HAMA scores in the observation group and the control group were (4.86 ±1.49) points and (7.98 ±2.10) points, respectively, which were significantly lower than those before treatment of (22.98 ±4.52) points and (23.87 ±3.10) points (P<0.05), and the observation group was also significantly lower than the control group (P<0.05). There were no significant difference in the incidence of somnolence, constipation, dry mouth, dizziness and other adverse reactions compared between the two groups. After treatment, the level of cortisol in the two groups were significantly lower than before treatment (P<0.05), and the level of cortisol in the observation group after treatment was also significantly lower than that of the control group (P<0.05). Conclusions buspirone in the treatment of schizophrenic agitation can promote the decline of HAMD score, thereby improving the therapeutic efficacy and safety. The mechanism may be related to the reduction of cortisol level.